Part 2 - Highlights of the San Antonio Breast Cancer Symposium 2023.
作者信息
Benson John R, Jatoi Ismail
机构信息
Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust & School of Medicine, Anglia Ruskin University, Cambridge, UK.
Division of Surgical Oncology, Dale H. Dorn Chair in Surgery, University of Texas Health Science Centre, San Antonio, TX 78240, USA.
出版信息
Future Oncol. 2024 Dec;20(40):3347-3350. doi: 10.1080/14796694.2024.2418797. Epub 2024 Oct 29.
Abstract
摘要
相似文献
1
Part 2 - Highlights of the San Antonio Breast Cancer Symposium 2023.第二部分 - 2023年圣安东尼奥乳腺癌研讨会亮点
Future Oncol. 2024 Dec;20(40):3347-3350. doi: 10.1080/14796694.2024.2418797. Epub 2024 Oct 29.
2
Part 1 - Highlights of the San Antonio Breast Cancer Symposium 2023.第一部分 - 2023年圣安东尼奥乳腺癌研讨会亮点
Future Oncol. 2024 Dec;20(40):3343-3345. doi: 10.1080/14796694.2024.2418804. Epub 2024 Oct 29.
3
Highlights of the San Antonio Breast Cancer Symposium 2015: part 2.2015年圣安东尼奥乳腺癌研讨会亮点：第二部分。
Future Oncol. 2016 Apr;12(7):897-900. doi: 10.2217/fon-2016-0044. Epub 2016 Feb 15.
4
Highlights of the San Antonio Breast Cancer Symposium 2015: part 1.2015年圣安东尼奥乳腺癌研讨会亮点：第一部分。
Future Oncol. 2016 Apr;12(7):893-6. doi: 10.2217/fon-2016-0043. Epub 2016 Feb 15.
5
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 2).针对降低死亡率和提高生活质量的乳腺癌治疗策略：2017 年圣安东尼奥乳腺癌研讨会（第 2 部分）。
Future Oncol. 2018 Aug;14(19):1893-1896. doi: 10.2217/fon-2018-0184. Epub 2018 Jul 18.
6
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 1).根据个体化差异制定乳腺癌治疗方案以降低死亡率和提高生活质量：2017 年圣安东尼奥乳腺癌研讨会（第 1 部分）。
Future Oncol. 2018 Aug;14(19):1889-1892. doi: 10.2217/fon-2018-0185. Epub 2018 Jul 18.
7
A systematic review of axillary nodal irradiation for the management of the axilla in patients with early-stage breast cancer.早期乳腺癌患者腋窝淋巴结照射治疗的系统评价。
Surg Oncol. 2022 Jun;42:101754. doi: 10.1016/j.suronc.2022.101754. Epub 2022 May 2.
8
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.前哨淋巴结活检与腋窝淋巴结清扫术在接受乳腺癌改良根治术且有 1-2 枚前哨淋巴结转移的患者中的应用：SINODAR-ONE 多中心随机临床试验的亚组分析及再次入组
Br J Surg. 2023 Aug 11;110(9):1143-1152. doi: 10.1093/bjs/znad215.
9
[San Antonio Breast Cancer Symposium 2011 (SABCS): what place will remain to the axillary dissection?].[2011年圣安东尼奥乳腺癌研讨会（SABCS）：腋窝淋巴结清扫术将处于何种地位？]
Gynecol Obstet Fertil. 2012 Apr;40(4):201-3. doi: 10.1016/j.gyobfe.2012.02.019. Epub 2012 Mar 29.
10
Highlights of the San Antonio Breast Cancer Symposium 2016: Part 2.圣安东尼奥乳腺癌研讨会 2016 年要点：第 2 部分。
Future Oncol. 2017 Jul;13(16):1365-1369. doi: 10.2217/fon-2017-0089. Epub 2017 Jul 7.
本文引用的文献
1
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2- early breast cancer.NATALEE研究的原理与试验设计：一项针对HR+/HER2-早期乳腺癌患者的辅助性瑞博西尼联合内分泌治疗与单纯内分泌治疗的III期试验。
Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. eCollection 2023.
2
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.帕博西尼联合氟维司群或来曲唑治疗激素受体阳性/人表皮生长因子受体 2 阴性的晚期乳腺癌内分泌敏感患者：随机 PARIS 试验的详细安全性分析。
Oncologist. 2023 Jan 18;28(1):23-32. doi: 10.1093/oncolo/oyac205.
3
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌无事件生存。
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
4
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.参加 POSITIVE 试验的女性是谁：一项旨在支持希望怀孕的年轻激素受体阳性乳腺癌幸存者的全球研究。
Breast. 2021 Oct;59:327-338. doi: 10.1016/j.breast.2021.07.021. Epub 2021 Aug 3.
5
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
6
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).阿贝西利联合内分泌治疗用于 HR+、HER2-、淋巴结阳性、高危、早期乳腺癌的辅助治疗（monarchE）。
J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20.
7
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.胚系 BRCA 突变与早发性乳腺癌（POSH）的结果：一项前瞻性队列研究。
Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.
Zotero 插件